Home>Topics>Stocks>MAP Pharmaceuticals

MAP Pharmaceuticals MAPP

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. New Morningstar Analyst Report for Pepco Holdings Inc

      Stock Reports

      Thu, 10 Jul 2014

      address regulatory lag.The cancelation of the $1.2 billion MAPP transmission project, which would have provided a generous 12 ..... Atlantic Power Pathway project, citing low demand. Absent MAPP , reliability-driven distribution and transmission spending

    2. Allergan Will Control Migraine Portfolio Through Planned MAP Acquisition

      Commentary

      Wed, 23 Jan 2013

      Allergan AGN announced it intends to acquire MAP Pharmaceuticals for approximately $950 million. The news is not particularly surprising because both companies formed a partnership in 2011 for

    3. MAP Pharma shares dive after FDA rejects migraine treatment

      Headlines

      Tue, 27 Mar 2012

      (Reuters) - Shares of MAP Pharmaceuticals Inc fell by a third in premarket trade on Tuesday, after health regulators rejected its orally inhaled treatment for migraine, but analysts remain...

    « Prev123Next »
    Content Partners